Retatrutide: a plain-English explainer

If you have been reading about GLP-1 weight-loss drugs, you have probably come across retatrutide, Eli Lilly's next-generation compound. At its core, retatrutide does the same job as semaglutide or tirzepatide, but adds a third receptor to the mix. Whether that addition translates into a meaningfully different medicine in practice is the question Phase 3 trials are working to answer.

What retatrutide actually is

Retatrutide is a once-weekly subcutaneous injection, a synthetic peptide designed to act simultaneously on three hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Eli Lilly's internal development name was LY3437943. The triple-agonist design was first described in a 2022 Cell Metabolism paper by Coskun and colleagues, covering the compound's discovery and early human proof-of-concept data^[1].

How the three receptors fit together

The GLP-1R pathway reduces appetite and slows gastric emptying. That is the same mechanism as semaglutide and the GLP-1R component of tirzepatide. The GIPR pathway appears to amplify those effects and may improve tolerability at higher doses; it is already part of tirzepatide's dual-agonist design. The glucagon receptor is the new piece. Activating it raises resting energy expenditure, meaning the body burns more calories at rest. In mouse models, the GCGR activation contributed to weight loss beyond what appetite suppression alone could explain^[1]. Whether that energy-expenditure effect translates meaningfully into humans is one of the open questions in the Phase 3 programme.

What the Phase 2 trial showed

The pivotal Phase 2 obesity trial, published in the New England Journal of Medicine in August 2023 by Jastreboff and colleagues, enrolled 338 adults and ran for 48 weeks^[2]. Weight loss was dose-dependent and substantial:

At the 4 mg dose, participants lost a mean of 17.1% of body weight. At 8 mg, the figure was 22.8%. At the maximum 12 mg dose, mean weight loss reached 24.2%, compared with 2.1% on placebo. The proportion of participants who lost 15% or more of their body weight ranged from 67% on 4 mg to 83% on 12 mg.

There was also a Phase 2 trial in type 2 diabetes, published in the Lancet in 2023 by Rosenstock and colleagues^[4], covering 281 participants over 36 weeks. It found retatrutide produced meaningful reductions in HbA1c alongside weight loss in that population as well.

The main safety signals were gastrointestinal: nausea, diarrhoea, vomiting and constipation, all dose-dependent and described as mostly mild to moderate. The trial also logged a dose-dependent increase in resting heart rate, peaking around week 24 before declining. That heart-rate signal was distinct from what GLP-1 monotherapy typically shows and appears to be related to the glucagon receptor component. For context on how those signals compare to other agents in the class, see the semaglutide and tirzepatide pages.

Where retatrutide stands today

Investigational. As of mid-2026, retatrutide has no approval from the FDA, the EMA, the MHRA, or any national regulator we track. Eli Lilly's Phase 3 programme, called TRIUMPH, spans at least six trials. TRIUMPH-1, the flagship obesity trial in adults without type 2 diabetes, reported a topline mean weight loss of 28.3% at 80 weeks on 12 mg in May 2026. That result has not yet been published in a peer-reviewed journal. TRIUMPH-Outcomes, the cardiovascular and kidney outcomes study, has a primary completion date of February 2029^[3].

The FDA has stated that retatrutide cannot be used in compounding under federal law because it is not an approved drug and is not on the 503A or 503B bulk substances lists. That position has not changed. If you are considering retatrutide or reading claims about compounded versions, the regulatory situation matters: the compound you might encounter from grey-market suppliers is not the same as the clinical trial product, and no regulator has assessed it for safety or efficacy.

What we do not know yet

Several questions remain open. First, durability: the Phase 2 trial ran 48 weeks; what happens to body weight at year two or year three on retatrutide is not yet published. Second, cardiovascular outcomes: the TRIUMPH-Outcomes trial is the event-driven study that will tell us whether the weight loss translates into fewer heart attacks and strokes, and it will not read out before 2029. Third, the glucagon receptor contribution in humans: the preclinical energy-expenditure signal is promising but human mechanistic data are limited. Fourth, long-term safety of continuous glucagon receptor activation is not yet fully characterised.

The medical disclaimer

This article is for educational and journalistic purposes only and does not constitute medical advice. Retatrutide is an investigational compound with no regulatory approval anywhere in the world as of this writing. Peptides discussed here may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before considering any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.